- Home
- KALU vs NVAX Comparison
KALU vs NVAX Comparison
Compare KALU & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALU
- NVAX
- Stock Information
- Founded
- KALU 1946
- NVAX 1987
- Country
- KALU United States
- NVAX United States
- Employees
- KALU N/A
- NVAX N/A
- Industry
- KALU Metal Fabrications
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KALU Industrials
- NVAX Health Care
- Exchange
- KALU Nasdaq
- NVAX Nasdaq
- Market Cap
- KALU 1.4B
- NVAX 1.3B
- IPO Year
- KALU 1991
- NVAX 1995
- Fundamental
- Price
- KALU $76.53
- NVAX $7.98
- Analyst Decision
- KALU Buy
- NVAX Buy
- Analyst Count
- KALU 3
- NVAX 7
- Target Price
- KALU $78.00
- NVAX $14.29
- AVG Volume (30 Days)
- KALU 82.5K
- NVAX 7.1M
- Earning Date
- KALU 10-22-2025
- NVAX 11-11-2025
- Dividend Yield
- KALU 4.02%
- NVAX N/A
- EPS Growth
- KALU 8.08
- NVAX N/A
- EPS
- KALU 3.33
- NVAX 2.54
- Revenue
- KALU $3,113,600,000.00
- NVAX $1,078,718,000.00
- Revenue This Year
- KALU $13.96
- NVAX $61.69
- Revenue Next Year
- KALU $11.52
- NVAX N/A
- P/E Ratio
- KALU $22.99
- NVAX $3.14
- Revenue Growth
- KALU 4.62
- NVAX 9.22
- 52 Week Low
- KALU $46.81
- NVAX $5.01
- 52 Week High
- KALU $97.00
- NVAX $15.22
- Technical
- Relative Strength Index (RSI)
- KALU 48.12
- NVAX 51.73
- Support Level
- KALU $73.91
- NVAX $7.63
- Resistance Level
- KALU $77.54
- NVAX $8.31
- Average True Range (ATR)
- KALU 1.78
- NVAX 0.35
- MACD
- KALU 0.11
- NVAX -0.00
- Stochastic Oscillator
- KALU 41.00
- NVAX 69.44
About KALU Kaiser Aluminum Corporation
Kaiser Aluminum Corp produces and sells semi-fabricated specialty aluminum products predominantly to industrial customers. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from the United States.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.